Patients’ Characteristics According to the Study Group
| Characteristics | With Telephonic Follow-up | Without Telephonic Follow-up | Both Groups | Proportion Difference (95% Confidence Interval) |
|---|---|---|---|---|
| Number of subjects | 535,898 | 962,910 | 1498,808 | |
| Sex | ||||
| Female | 276,658 (51.63%) | 513,541 (53.33%) | 790,199 (52.72%) | |
| Male | 259,240 (48.37%) | 449,369 (46.67%) | 708,609 (47.28%) | 1.71 (1.54, 1.87) |
| Age group | ||||
| 20 to 39 years old | 307,878 (57.45%) | 576,422 (59.86%) | 884,300 (59%) | −2.41 (−2.58, −2.25) |
| 40 to 59 years old | 193,696 (36.14%) | 311,931 (32.39%) | 505,627 (33.74%) | 3.75 (3.59, 3.91) |
| 60 or more years old | 34,324 (6.40%) | 74,557 (7.74%) | 108,881 (7.26%) | −1.34 (−1.42, −1.25) |
| Occupation | ||||
| Employee | 334,484 (62.42%) | 603,120 (62.64%) | 937,604 (62.56%) | −0.22 (−0.38, −0.06) |
| Housewife | 37,804 (7.05%) | 65,434 (6.80%) | 103,238 (6.89%) | 0.26 (0.17, 0.34) |
| Other | 163,610 (30.53%) | 294,356 (30.57%) | 457,966 (30.56%) | −0.04 (−0.19, 0.11) |
| Epidemic wave | ||||
| 2nd wave | 143,578 (26.79%) | 165,293 (17.17%) | 308,871 (20.61%) | 9.63 (9.49, 9.77) |
| 3rd wave | 229,929 (42.91%) | 253,596 (26.34%) | 483,525 (32.26%) | 16.57 (16.41, 16.73) |
| 4th wave | 162,391 (30.3%) | 544,021 (56.5%) | 706,412 (47.13%) | −26.2 (−26.5, −26.04) |
| Geographical region | ||||
| South | 101,093 (18.86%) | 136,131 (14.14%) | 237,224 (15.83%) | 4.73 (4.60, 4.85) |
| Center | 303,098 (56.56%) | 600,880 (62.4%) | 903,978 (60.31%) | −5.84 (−6.01, −5.68) |
| North | 131,707 (24.58%) | 225,899 (23.46%) | 357,606 (23.86%) | 1.12 (0.97, 1.26) |
| Comorbid conditions | ||||
| Obesity | 52,662 (9.83%) | 76,340 (7.93%) | 129,002 (8.61%) | 1.90 (1.80, 2.00) |
| Hypertension | 52,532 (9.80%) | 89,473 (9.29%) | 142,005 (9.47%) | 0.51 (0.41, 0.61) |
| Diabetes | 34,464 (6.43%) | 60,259 (6.26%) | 94,723 (6.32%) | 0.17 (0.09, 0.25) |
| Tobacco consumption | 27,233 (5.08%) | 45,633 (4.74%) | 72,866 (4.86%) | 0.34 (0.27, 0.42) |
| Asthma | 8,262 (1.54%) | 14,415 (1.5%) | 22,677 (1.51%) | 0.04 (0.00, 0.09) |
| COPD | 1,697 (0.32%) | 43,16 (0.45%) | 6,013 (0.40%) | −0.13 (−0.15, −0.11) |
| Cardiovascular disease | 2,274 (0.42%) | 54,72 (0.57%) | 7,746 (0.52%) | −0.14 (−0.17, −0.12) |
| Immunosuppression | 1,510 (0.28%) | 28,77 (0.30%) | 4,387 (0.29%) | −0.02 (−0.03, 0.00) |
| HIV infection | 1,797 (0.34%) | 23,86 (0.25%) | 4,183 (0.28%) | 0.09 (0.07, 0.11) |
| Chronic kidney disease | 2,026 (0.38%) | 61,35 (0.64%) | 8,161 (0.54%) | −0.26 (−0.28, −0.24) |
| Any medical condition | 132,496 (24.72%) | 214,076 (22.23%) | 346,572 (23.12%) | 2.49 (2.35, 2.63) |
| Medical outcomes | ||||
| Emergency room attention | 24,008 (4.48%) | 61,328 (6.37%) | 853,36 (5.69%) | −1.89 (−1.96, −1.82) |
| Hospitalization | 22,255 (4.15%) | 62,018 (6.44%) | 84,273 (5.62%) | −2.29 (−2.36, −2.22) |
| Endotracheal intubation | 1,896 (0.35%) | 6,301 (0.65%) | 8,197 (0.55%) | −0.30 (−0.32, −0.28) |
| All-cause death | 6,903 (1.29%) | 28,368 (2.95%) | 35,271 (2.35%) | −1.66 (−1.70, −1.61) |
| Hospitalization or death | 23,351 (4.36%) | 63,756 (6.62%) | 87,107 (5.81%) | −2.26 (−2.34, −2.19) |
Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus.
Data are presented as number (%).
Proportion difference between groups with and without telephonic follow-up.